Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).

被引：0

作者：

Hong, David S.

Strickler, John H.

Fakih, Marwan

Falchook, Gerald Steven

Li, Bob T.

Durm, Greg Andrew

Burns, Timothy F.

Ramalingam, Suresh S.

Goldberg, Sarah B.

Frank, Richard C.

Marrone, Kristen

Shu, Catherine A.

Gandara, David R.

Soman, Neelesh

Henary, Haby Adel

Govindan, Ramaswamy

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Duke Univ, Sch Med, Durham, NC USA

[3] City Hope Comprehens Med Ctr, Duarte, CA USA

[4] Sarah Cannon Res Inst, Denver, CO USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA

[7] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA

[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[9] Yale Sch Med, New Haven, CT USA

[10] Nuvance Hlth, Norwalk, CT USA

[11] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[12] Columbia Univ, Med Ctr, New York, NY USA

[13] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA

[14] Amgen Inc, Translat Med, Thousand Oaks, CA 91320 USA

[15] Amgen Inc, Thousand Oaks, CA 91320 USA

[16] Washington Univ, Sch Med, St Louis, MO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS2669

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS2669

引用

页数：4

共 50 条

[1] A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)
Hong, David S.
Yaeger, Rona
Kuboki, Yasutoshi
Masuishi, Toshiki
Barve, Minal A.
Falchook, Gerald Steven
Govindan, Ramaswamy
Sohal, Davendra
Kasi, Pashtoon Murtaza
Burns, Timothy F.
Langer, Corey J.
Puri, Sonam
Chan, Emily
Jafarinasabian, Pegah
Ngarmchamnanrith, Gataree
Rehn, Marko
Tran, Qui
Gandara, David R.
Strickler, John H.
Fakih, Marwan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[2] Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
Fakih, Marwan
Durm, Greg Andrew
Govindan, Ramaswamy
Falchook, Gerald Steven
Soman, Neelesh
Henary, Haby Adel
Hong, David S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101)
Fakih, M.
Durm, G.
Govindan, R.
Falchook, G.
Soman, N.
Henary, H.
Hong, D. S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S28
[4] CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Hong, David S.
Kuo, James
Sacher, Adrian G.
Barlesi, Fabrice
Besse, Benjamin
Kuboki, Yasutoshi
Dy, Grace K.
Dembla, Vikas
Krauss, John C.
Burns, Timothy F.
Kim, June
Henary, Haby
Ngarmchamnanrith, Gataree
Li, Bob T.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)
Gandara, David
Marrone, Kristen
Govindan, Ramaswamy
Skoulidis, Ferdinandos
Durm, Gregory
Clarke, Jeffrey
Frank, Richard
Krauss, John
Snyder, Wendy
Dai, Tian
Mather, Omar
Cifuentes, Paul
Hindoyan, Antreas
Anderson, Abraham
Burns, Timothy
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[6] Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study.
Langer, Corey J.
Galot, Rachel
Prenen, Hans
Hong, David S.
Victoria, Ivan
Salgia, Ravi
Chenard-Poirier, Maxime
Furqan, Muhammad
Chan, Emily
Nolte-Hippenmeyer, Jane
Xia, Caihong
Li, Bob T.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors
Ramalingam, Suresh
Fakih, Marwan
Strickler, John
Govindan, Ramaswamy
Li, Bob T.
Goldberg, Sarah
Gandara, David
Burns, Timothy
Barve, Minal
Shu, Catherine
Frank, Richard
Sohal, Davendra
Jafarinasabian, Pegah
Dai, Tian
Mather, Omar
Hong, David
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[8] CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
Fakih, M.
Falchook, G. S.
Hong, D. S.
Yaeger, R. D.
Chan, E.
Mather, O.
Cardona, P.
Dai, T.
Strickler, J.
ANNALS OF ONCOLOGY, 2021, 32 : S551 - S551
[9] Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation
Waizenegger, Irene C.
Lu, Hengyu
Thamer, Claus
Savarese, Fabio
Gerlach, Daniel
Rudolph, Dorothea
Vellano, Christopher P.
Marotti, Marcelo
Heymach, John
Kopetz, Scott
Heffernan, Timothy P.
Marszalek, Joseph R.
Petronczki, Mark P.
Hofmann, Marco H.
Kraut, Norbert
CANCER RESEARCH, 2022, 82 (12)
[10] Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer
Govindan, R.
Fakih, M. G.
Price, T. J.
Falchook, G. S.
Desai, J.
Kuo, J. C.
Strickler, J. H.
Krauss, J. C.
Li, B. T.
Denlinger, C. S.
Durm, G.
Ngang, J.
Henary, H.
Ngarmchamnanrith, G.
Rasmussen, E.
Morrow, P. K.
Hong, D. S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1191 - S1192

← 1 2 3 4 5 →